Light-activated nanomaterials for tumor immunotherapy

Fang Wang; Huijuan Duan; Weizhe Xu; Gang Sheng; Zhaogang Sun; Hongqian Chu

doi:10.3389/fchem.2022.1031811

Light-activated nanomaterials for tumor immunotherapy

Front Chem. 2022 Oct 7:10:1031811. doi: 10.3389/fchem.2022.1031811. eCollection 2022.

Authors

Fang Wang^{1

2}, Huijuan Duan^{1

2}, Weizhe Xu^{1

2}, Gang Sheng^{1

2}, Zhaogang Sun^{1

2}, Hongqian Chu^{1

2}

Affiliations

¹ Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, Beijing, China.
² Beijing Key Laboratory in Drug Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.

Abstract

Tumor immunotherapy mainly relies on activating the immune system to achieve antitumor treatment. However, the present tumor immunotherapy used in the clinic showed low treatment efficacy with high systematic toxicity. To overcome the shortcomings of traditional drugs for immunotherapy, a series of antitumor immunotherapies based on nanomaterials have been developed to enhance the body's antitumor immune response and reduce systematic toxicity. Due to the noninvasiveness, remote controllability, and high temporal and spatial resolution of light, photocontrolled nanomaterials irradiated by excitation light have been widely used in drug delivery and photocontrolled switching. This review aims to highlight recent advances in antitumor immunotherapy based on photocontrolled nanomaterials. We emphasized the advantages of nanocomposites for antitumor immunotherapy and highlighted the latest progress of antitumor immunotherapy based on photoactivated nanomaterials. Finally, the challenges and future prospects of light-activated nanomaterials in antitumor immunity are discussed.

Keywords: antitumor immunity; immunotherapy; light-activated; nanomaterials; synergistic therapy.

Publication types

Review